Status:
COMPLETED
GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia
Lead Sponsor:
Herlev Hospital
Collaborating Sponsors:
University of Copenhagen
The Danish Medical Research Council
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
35+ years
Brief Summary
In order to investigate the mechanisms underlying the hyperglucagonemia characterizing patients with type 2 diabetes mellitus (T2DM) we wish to test the following hypothesis: Do pancreatic alpha-cells...
Detailed Description
Patients with T2DM are not able to suppress their secretion of glucagon after a meal or after oral ingestion of glucose. Patients actually respond with pathological high plasmaglucagon concentrations ...
Eligibility Criteria
Inclusion
- Caucasians with diet and/or tablet treated T2DM of at least 3 months duration (diagnosed according to the criterias of the World Health Organization (WHO))
- Normal Hemoglobin
- Prior Informed Consent
Exclusion
- Liver disease (ALAT/ASAT \> 2 x upper normal value)
- Diabetic nephropathy (se-creatinin \> 130 um and/or albuminuria
- Treatment with drugs that cannot be discontinued for 12 hours
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00716170
Start Date
July 1 2008
End Date
July 1 2009
Last Update
November 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology J, Herlev Hospital
Herlev, Herlev, Denmark, 2730